BEMPEDOIC ACID - Generic Drug Details

What are the generic sources for bempedoic acid and what is the scope of freedom to operate?

Bempedoic acid is the generic ingredient in two branded drugs marketed by Esperion Theraps Inc and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bempedoic acid has eighty-one patent family members in twenty-four countries.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for BEMPEDOIC ACID

International Patents:	81
US Patents:	8
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	31
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEMPEDOIC ACID
What excipients (inactive ingredients) are in BEMPEDOIC ACID?	BEMPEDOIC ACID excipients list
DailyMed Link:	BEMPEDOIC ACID at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEMPEDOIC ACID

Constraining patent/regulatory exclusivity:

11,613,511

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BEMPEDOIC ACID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Southern California	PHASE2
Tufts Medical Center	PHASE2
University of Pittsburgh	PHASE2

See all BEMPEDOIC ACID clinical trials

Generic filers with tentative approvals for BEMPEDOIC ACID

Applicant	Application No.	Strength	Dosage Form
		180MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for BEMPEDOIC ACID

Drug Class	Adenosine Triphosphate-Citrate Lyase Inhibitor
Mechanism of Action	Adenosine Triphosphate-Citrate Lyase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for BEMPEDOIC ACID

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for BEMPEDOIC ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLETOL	Tablets	bempedoic acid	180 mg	211616	9	2024-02-21

US Patents and Regulatory Information for BEMPEDOIC ACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	7,335,799			Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes	7,335,799			Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	11,744,816
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	12,404,227			Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	12,398,087		Y	Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes	12,404,227			Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes	11,744,816

Expired US Patents for BEMPEDOIC ACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020	9,624,152
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020	10,118,881
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020	9,000,041
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020	8,497,301
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020	10,941,095

EU/EMA Drug Approvals for BEMPEDOIC ACID

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nilemdo	bempedoic acid	EMEA/H/C/004958Nilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.	Authorised	no	no	no	2020-04-01

International Patents for BEMPEDOIC ACID

Country	Patent Number	Title	Estimated Expiration
Australia	2020295503
Australia	2020296094
Australia	2025203232
Brazil	112021025928
Brazil	112021025964
Canada	3144371
Canada	3144372

Supplementary Protection Certificates for BEMPEDOIC ACID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	640	Finland
2404890	301062	Netherlands		PRODUCT NAME: BEMPEDONZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT, SOLVAAT OF MENGSEL DAARVAN; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	122020000048	Germany		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 20200327
2404890	C 2020 031	Romania		PRODUCT NAME: ACID BEMPEDOIC, SAU O SARE, HIDRAT, SOLVAT ACCEPTABILE FARMACEUTIC SAU AMESTECUL ACESTORA; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2404890	CA 2020 00041	Denmark		PRODUCT NAME: BEMPEDOINSYRE ELLER ET/EN FARMACEUTISK ACCEPTABEL(T) SALT, HYDRAT, SOLVAT ELLER BLANDING DERAF; REG. NO/DATE: EU/1/20/1424 20200331
2404890	2020/037	Ireland		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; REGISTRATION NO/DATE: EU/1/20/1424 20200331

Last updated: June 19, 2026

Bempedoic Acid Market Dynamics and Financial Trajectory (2026 Update)

Bempedoic acid, an oral ATP-citrate lyase (ACL) inhibitor for hypercholesterolemia, has moved from early adoption to broader lipid-disease positioning alongside statins and ezetimibe. Financial trajectory has been driven by (1) label scope in primary hyperlipidemia and mixed dyslipidemia, (2) uptake in patients seeking statin alternatives or add-on therapy, and (3) competitive pressure from injectable PCSK9 inhibitors, combination oral regimens (statin/ezetimibe, and fixed-dose statin combinations), and other newer LDL-lowering assets entering the market.

How are bempedoic acid sales trending and what drives revenue growth?

Direct drivers of bempedoic acid revenue growth

• Concentrated demand in oral LDL-lowering add-on settings: Bempedoic acid is positioned for incremental LDL-C reduction in patients not at goal with statins, or in statin-intolerant populations.
• Payer dynamics for oral therapies: Oral agents often face different formulary barriers than injectables, with fewer prior authorization steps in some plan designs.
• Switching and persistence effects: Market share gains typically come from patients switching from ezetimibe-only or “statin not tolerated” pathways, then adding bempedoic acid for additional LDL-C reduction.

Direct drivers of revenue slowdowns or volatility

• Formulary consolidation around “first-line” sequences: Many commercial formularies route patients through statins and/or ezetimibe before adding a newer agent.
• PCSK9 pricing and outcomes contracting: Even with high list prices, contracting and outcomes-based payer arrangements for PCSK9 inhibitors can compress uptake for oral alternatives.
• Safety-driven switching: Bempedoic acid’s adverse-event profile (notably effects related to gout/hyperuricemia and tendon injury warnings) can influence persistence in certain segments, which can dampen conversion rates.

What is the current market size exposure for LDL-C therapies where bempedoic acid competes?

Bempedoic acid competes in a large and expanding cardiovascular risk pool that includes:

• Primary hypercholesterolemia and mixed dyslipidemia (broad outpatient prevalence in the US)
• Patients requiring additional LDL-C lowering after statins or ezetimibe
• Statin-intolerant populations seeking oral options

The competitive field is dominated by:

• Statins (generic, strongest default payer position)
• Ezetimibe (generic)
• Fixed-dose combinations (statin/ezetimibe products)
• PCSK9 inhibitors (evolocumab and alirocumab; commercial and outcomes-based contracting)
• Inclisiran and other pipeline PCSK9-platform assets (where uptake depends on labeling, administration model, and payer adoption)
• Newer oral LDL-lowering mechanisms in development (market pressure on bempedoic acid’s “add-on” niche)

Key implication for financial trajectory: Bempedoic acid’s revenue ceiling is constrained by the willingness of payers to cover after cheaper generic step-therapy, and by the extent to which injectables win outcomes-based contracts for eligible patients.

Which companies market bempedoic acid and how does ownership structure affect financial performance?

Bempedoic acid is marketed primarily by Esperion Therapeutics in the US (historical developer/rights holder). In practice, near-term commercial financials depend on:

• Product portfolio scale (Esperion’s development-to-commercial pipeline breadth versus single-asset concentration)
• Co-promotion or distribution arrangements (typical for specialty launches)
• Net-to-gross pressure driven by contracting, rebates, and patient assistance

From a market-dynamics standpoint, Esperion’s financial trajectory is tightly coupled to:

• Launch ramp and refill persistence
• Prescription-to-coverage conversion in managed care
• Degree of formulary exclusion or “tiering” changes year over year

What has the bempedoic acid launch-to-adoption curve looked like?

Early-stage dynamics (typical for a novel oral lipid agent)

• Higher share gains in patients seeking non-statin pathways or add-on therapy
• Gradual payer acceptance through local coverage policies
• Uptake that correlates with prescriber familiarity and LDL-C response evidence

Mature-stage dynamics

• Growth becomes more dependent on:
  • conversion of patients from ezetimibe-only
  • penetration into statin-intolerant “gap-filling”
  • sustained contracting access

Net effect for financial trajectory: Expect revenue growth to transition from “awareness-led” to “access-led.” In that phase, pricing, formulary position, and persistence drive annual revenue variability.

How does bempedoic acid compare with PCSK9 inhibitors in market share potential?

Competitive cost and access structure

• PCSK9 inhibitors can achieve payer affordability through rebates and contracting, narrowing price differences.
• Injectable therapies may gain access under outcomes contracts, especially for high-risk populations.

Patient experience

• Oral dosing favors adherence for many patients.
• Injectables can be preferred where oral add-on is blocked by step therapy or where LDL targets require larger per-dose reductions.

Market-share implication

• Bempedoic acid generally benefits where payers and prescribers want an oral alternative before moving to expensive injectables.
• PCSK9 inhibitors retain strong positioning when payer coverage is broad and when outcomes contracts reduce effective cost.

What is the role of combination products (bempedoic acid + ezetimibe) in financial performance?

Combination therapy is a major financial lever because:

• It reduces pill burden versus sequencing
• It can improve adherence and persistence
• It can strengthen payer acceptance as a single therapeutic step for LDL-C targets

In lipid management, combo products often:

• accelerate time-to-therapy intensification
• increase share versus monotherapy in managed care

Financial trajectory impact: combination formulations typically increase average prescriptions per patient and improve net revenue stability by lowering discontinuation and improving coverage conversion.

What do payer and formulary dynamics imply for bempedoic acid net pricing?

For specialty oral cardiovascular therapies, net pricing is shaped by:

• Rebate agreements and commercial discounts
• Tier placement (preferred vs non-preferred)
• Prior authorization requirements and step-therapy rules
• Patient assistance availability

Key financial impact: even when gross sales rise, net sales can lag due to coverage tightening, tier changes, and rebate renegotiations. This pattern is common when competing injectables broaden access or when newer oral LDL agents enter the market.

How will bempedoic acid exclusivity, patent life, and generic risk affect future revenue?

Revenue durability for bempedoic acid is determined by:

• Composition and method-of-use patent coverage
• Formulation and crystalline form patents (if applicable)
• Regulatory exclusivity related to new chemical entity (NCE) and any secondary exclusivities

Generic entry risk channels

• Section 505(b)(2) pathways for reformulations or prodrugs
• ANDA Paragraph IV challenges once relevant patents are carved out
• Bioequivalence-only generics if only nonblocking patents remain at the ANDA filing point

Financial trajectory impact: if patent litigation narrows blocking coverage, revenue can experience step-change declines around authorized generic or generic launch timing.

What Orange Book status applies to bempedoic acid and its combinations?

Bempedoic acid market dynamics are closely linked to Orange Book listings for:

• the reference drug
• any listed combination fixed-dose products
• any listed method-of-use patents

Orange Book status determines:

• whether ANDA challengers file Paragraph IV
• whether settlements impose “carve-out” launch dates
• the effective runway for line extensions and brand reinforcement

What patent litigation and settlement scenarios would matter commercially?

For oral lipid agents, commercially material litigation typically centers on:

• injunction outcomes affecting ability to market generics
• settlement-triggered “early entry” dates
• carve-outs limiting launch to certain strengths, dosage forms, or indications

Financial trajectory impact: brand revenue typically declines sharply when generics enter without meaningful brand-exclusive settlements. Conversely, long-term exclusivity stability supports predictable revenue until competitive alternatives gain coverage.

How do FDA label scope and clinical outcomes data influence uptake?

FDA label scope affects:

• who can be prescribed without off-label risk
• how payers justify coverage
• whether clinicians adopt earlier in the treatment algorithm

Uptake is also influenced by:

• perceived magnitude and durability of LDL-C reductions
• tolerability in comorbid cohorts (e.g., gout history)
• clinician confidence in real-world adherence and persistence

Financial trajectory impact: label clarity and strong LDL-C performance support continued conversion from existing generic pathways; negative real-world tolerability signals can slow persistence.

Which competitive drugs most directly compress bempedoic acid demand?

Bempedoic acid competes for treatment intensification and secondary-line preference against:

• Ezetimibe (generic)
• Statin/ezetimibe fixed-dose combinations (generic + brand variants depending on product)
• PCSK9 inhibitors (injectable high potency; strong outcomes narratives)
• Other LDL-lowering pipeline assets entering formulary pathways

Market dynamics implication: bempedoic acid’s growth is strongest when it is the “next step” after ezetimibe or in statin-intolerant patients. It slows when payers and clinicians jump directly to injectable therapies or when combination fixed-dose products capture intensified share.

What manufacturing and distribution risks affect bempedoic acid availability and revenue?

Availability is a secondary but real driver:

• supply chain stability affects missed prescriptions and backorders
• contract manufacturing allocation can affect fill rates during ramp phases

Financial trajectory impact: sustained supply can support persistence and repeat prescribing, while repeated disruptions lead to irreversible physician switching during shortages.

Revenue outlook scenarios: what would drive upside or downside?

Upside scenario drivers

• expanding preferred formulary access
• increased uptake of fixed-dose combination regimens
• improved persistence with better patient selection
• restricted coverage for competing injectables or higher copays for alternatives

Downside scenario drivers

• intensified step therapy requiring failure of additional generics
• broader outcomes contracting for PCSK9 inhibitors that pushes eligible patients away from oral add-ons
• safety-related discontinuations in key treated cohorts
• generic or authorized generic pressures once exclusivity/patent barriers fall

Key metrics investors and licensors track for bempedoic acid financial trajectory

1. Prescription growth and share of new starts in dyslipidemia lines of therapy
2. Net-to-gross ratio and rebating trends
3. Persistence (TRx per patient) at 6 and 12 months
4. Formulary position (tiering and prior authorization frequency)
5. Combination mix (monotherapy vs fixed-dose combination)
6. Payer coverage velocity (time-to-approval by major PBMs)

Key Takeaways

• Bempedoic acid’s financial trajectory depends on managed care access and persistence, not only on gross prescription growth.
• Growth is anchored in oral add-on and statin-intolerant use cases, with combination products as a major margin-stabilizer.
• Competitive compression is most likely from PCSK9 contracting strategies and intensified step therapy around generic ezetimibe/statin combinations.
• Patent and exclusivity posture governs the long-term revenue runway and determines the magnitude and timing of generic-entry risk.
• The highest-information indicators for future performance are net-to-gross, formulary access changes, persistence, and combination mix.

FAQs

Will bempedoic acid lose market share if PCSK9 inhibitor contracting expands?

Yes. Broader outcomes-based contracting can shift eligible patients toward injectables, reducing the share of oral add-on pathways.

How much does combination bempedoic acid + ezetimibe change revenue versus monotherapy?

Combination products typically increase total covered patient starts and improve persistence, often raising prescription growth and smoothing discontinuations.

What determines whether generics can enter bempedoic acid before patent expiry?

Orange Book-listed blocking patents, Paragraph IV outcomes, and any settlement-driven launch dates determine whether early entries occur.

Do safety signals affect real-world adoption of bempedoic acid?

Yes. Discontinuation risk and prescriber patient selection in gout-prone cohorts can reduce persistence and slow new-start conversion.

What payer actions most directly influence bempedoic acid net sales?

Tier moves, prior authorization tightening, and rebate renegotiations can reduce net pricing even when gross demand stays stable.

---

References (APA)

No sources were provided in the prompt.